Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Immune Therapeutics

OTCPK:IMUN
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMUN
OTCPK
$7M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Immune Therapeutics, Inc., a late development-stage biopharmaceutical company, focuses on the development, commercialization, and licensing of prescription medications for humans, animals, and pets worldwide. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
  • Immune Therapeutics has significant price volatility in the past 3 months.
IMUN Share Price and Events
7 Day Returns
28.7%
OTCPK:IMUN
3.5%
US Biotechs
2.4%
US Market
1 Year Returns
124.3%
OTCPK:IMUN
4.6%
US Biotechs
-10%
US Market
IMUN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Immune Therapeutics (IMUN) 28.7% 137.9% 220.4% 124.3% -63.5% -74.3%
US Biotechs 3.5% -3.2% -2.4% 4.6% 16.3% -8.9%
US Market 2.4% -11% -19.4% -10% 9.6% 21.1%
1 Year Return vs Industry and Market
  • IMUN outperformed the Biotechs industry which returned 4.6% over the past year.
  • IMUN outperformed the Market in United States of America which returned -10% over the past year.
Price Volatility
IMUN
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Immune Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether Immune Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Immune Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Immune Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is $0.0157.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Immune Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Immune Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:IMUN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.01
OTCPK:IMUN Share Price ** OTCPK (2020-04-07) in USD $0.02
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 16.66x
United States of America Market PE Ratio Median Figure of 2,948 Publicly-Listed Companies 12.95x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Immune Therapeutics.

OTCPK:IMUN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:IMUN Share Price ÷ EPS (both in USD)

= 0.02 ÷ -0.01

-2.09x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immune Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.
  • Immune Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Immune Therapeutics's expected growth come at a high price?
Raw Data
OTCPK:IMUN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.09x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.84x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.92x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Immune Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Immune Therapeutics's assets?
Raw Data
OTCPK:IMUN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.03
OTCPK:IMUN Share Price * OTCPK (2020-04-07) in USD $0.02
United States of America Biotechs Industry PB Ratio Median Figure of 432 Publicly-Listed Biotechs Companies 2.61x
United States of America Market PB Ratio Median Figure of 5,162 Publicly-Listed Companies 1.26x
OTCPK:IMUN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:IMUN Share Price ÷ Book Value per Share (both in USD)

= 0.02 ÷ -0.03

-0.53x

* Primary Listing of Immune Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Immune Therapeutics has negative assets, we can't compare the value of its assets to the US Biotechs industry average.
X
Value checks
We assess Immune Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Immune Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Immune Therapeutics expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immune Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.9%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Immune Therapeutics expected to grow at an attractive rate?
  • Unable to compare Immune Therapeutics's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Immune Therapeutics's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare Immune Therapeutics's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:IMUN Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 17.9%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:IMUN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:IMUN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 0 0 -3
2019-06-30 0 0 -5
2019-03-31 0 -1 -8
2018-12-31 0 -1 -8
2018-09-30 0 -1 -11
2018-06-30 0 -2 -10
2018-03-31 0 -2 -5
2017-12-31 -2 -7
2017-09-30 0 -2 -9
2017-06-30 0 -3 -11
2017-03-31 0 -3 -15
2016-12-31 0 -3 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Immune Therapeutics is high growth as no earnings estimate data is available.
  • Unable to determine if Immune Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:IMUN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Immune Therapeutics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:IMUN Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.01
2019-06-30 -0.01
2019-03-31 -0.02
2018-12-31 -0.02
2018-09-30 -0.03
2018-06-30 -0.03
2018-03-31 -0.02
2017-12-31 -0.02
2017-09-30 -0.03
2017-06-30 -0.04
2017-03-31 -0.07
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Immune Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Immune Therapeutics's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Immune Therapeutics's filings and announcements here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Immune Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Immune Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Immune Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Immune Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Immune Therapeutics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Immune Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Immune Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Immune Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Immune Therapeutics Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:IMUN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.05 -3.42 2.44 -0.04
2019-06-30 0.05 -5.08 2.70 -0.04
2019-03-31 0.05 -8.27 3.72 0.01
2018-12-31 0.11 -8.18 4.00 0.14
2018-09-30 0.07 -10.88 4.61 0.22
2018-06-30 0.07 -9.66 5.02 0.33
2018-03-31 0.07 -5.36 4.42 0.41
2017-12-31 -7.32 4.92 0.40
2017-09-30 0.00 -8.73 5.21 0.46
2017-06-30 0.00 -11.28 6.40 0.65
2017-03-31 0.00 -15.49 7.57 0.58
2016-12-31 0.00 -19.52 9.10 0.44
2016-09-30 0.01 -19.64 9.65 0.60
2016-06-30 0.01 -19.54 9.63 0.41
2016-03-31 0.02 -18.06 9.36 0.76
2015-12-31 0.02 -14.24 9.00 0.96
2015-09-30 0.01 -21.87 9.85 1.40
2015-06-30 0.01 -28.93 13.55 1.60
2015-03-31 0.00 -33.07 15.88 3.22
2014-12-31 -48.25 23.52 7.21
2014-09-30 -82.20 54.40 12.95
2014-06-30 -91.24 54.13 19.06
2014-03-31 -109.34 63.15 23.14
2013-12-31 -106.06 60.64 21.95
2013-09-30 -233.93 74.52 20.44
2013-06-30 -214.30 69.13 14.05

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Immune Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if Immune Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Immune Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess Immune Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Immune Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Immune Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Immune Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Immune Therapeutics's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Immune Therapeutics has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Immune Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Immune Therapeutics has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Immune Therapeutics Company Filings, last reported 6 months ago.

OTCPK:IMUN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 -13.47 5.63 0.01
2019-06-30 -12.53 5.58 0.02
2019-03-31 -11.75 5.48 0.01
2018-12-31 -11.25 5.19 0.01
2018-09-30 -10.72 4.80 0.01
2018-06-30 -9.61 4.41
2018-03-31 -11.16 5.17 0.03
2017-12-31 -11.10 4.82 0.01
2017-09-30 -8.35 4.36 0.02
2017-06-30 -7.86 4.31 0.04
2017-03-31 -10.29 4.74 0.10
2016-12-31 -9.12 4.23 0.07
2016-09-30 -7.46 3.57 0.02
2016-06-30 -6.93 3.46 0.06
2016-03-31 -6.19 2.84 0.13
2015-12-31 -5.96 2.79 0.02
2015-09-30 0.94 1.84 0.15
2015-06-30 1.22 1.46 0.02
2015-03-31 1.70 1.01 0.03
2014-12-31 2.35 0.51 0.19
2014-09-30 13.88 0.10 0.06
2014-06-30 13.27 1.59 0.06
2014-03-31 14.78 1.59 0.23
2013-12-31 16.63 1.01 0.41
2013-09-30 17.02 1.05 0.21
2013-06-30 17.93 1.00 0.23
  • Immune Therapeutics has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if Immune Therapeutics's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Immune Therapeutics has less than a year of cash runway based on current free cash flow.
  • Immune Therapeutics has less than a year of cash runway if free cash flow continues to reduce at historical rates of -29.6% each year.
X
Financial health checks
We assess Immune Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Immune Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Immune Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Immune Therapeutics dividends.
If you bought $2,000 of Immune Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Immune Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Immune Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:IMUN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 67 Stocks 2.1%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 2.9%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.9%
United States of America Top 25% Dividend Yield 75th Percentile 5.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Immune Therapeutics has not reported any payouts.
  • Unable to verify if Immune Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Immune Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Immune Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Immune Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Immune Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Immune Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Immune Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Handley
TENURE AS CEO 0.6 years
CEO Bio

Mr. Michael Kevin Handley, also known as Mike, serves as Chief Executive Officer and Director of Immune Therapeutics, Inc. since September 2019. Mr. Handley serves as Chief Executive Officer and Chairman at Aletheia Therapeutics Corp. Mr. Handley served as the Chief Executive Officer and Director at Armis Biopharma, Inc. since 2012. He served as the Chief Development Officer of Reven Pharmaceuticals, Inc. and serves as its Director. Mr. Handley was responsible for the creation and execution of a strategy that culminate in the commercialization of the Reven Pharmaceutical product line. He has more than a decade of quality, clinical and regulatory experience in the healthcare field. He has been a life science business professional with cross-functional experience in drug/device commercialization, operations, mergers/acquisitions, regulatory/clinical affairs, venture formation/financing, market development and partnering/licensing. Mr. Handley maintains an extensive background in the life science sector, with cross-functional experience in product commercialization, regulatory and clinical affairs, operations, mergers and acquisitions, financing, market development and partnering/licensing. He has founded multiple health industry enterprises and held executive, management and advisory positions in a substantial number of leading public and private pharmaceutical and biotechnology companies. Mr. Handley retains an expansive history in drug development with multiple patents and peer-reviewed publications in the areas of oncology, anti-infectives, inflammation and neuroscience. He has assisted or led in the global commercialization of seventeen products that account for over six billion dollars in sales annually and has secured millions of dollars in private equity and venture capital for numerous high growth organizations. He was a Senior Principal of PRTM Management Consultants, Inc. He has drug discovery experience including multiple patents and peer-reviewed publications in the areas of oncology and neuroscience. He has lead management teams in a variety of business capacities including development of global corporate strategies for numerous public and private biotechnology and pharmaceutical companies. He has assisted or led in the global commercialization of seventeen devices and drugs that account for over three billion dollars of sales annually. He has experience leading management teams in a variety of capacities in high growth organizations and has secured millions of dollars in venture capital. He served as Vice President of Quality Clinical and Regulatory Affairs at Vessix Vascular, Inc. (acquired by Boston Scientific) since October 2010. He served as Director of Global Regulatory Affairs and Compliance and Chief Compliance Officer of The Spectranetics Corporation (acquired by Phillips). He served as the Vice President of Global Regulatory Affairs and Compliance at The Spectranetics Corporation since January 2009. Mr. Handley joined Spectranetics in 2007 as Manager of Regulatory Affairs and served as its Director, Global Regulatory Affairs and Compliance and Chief Compliance Officer. He was the Founder of AccelaPure Corporation and served as its Chief Executive Officer from May 2005 to February 2007 and was its Vice President of Regulatory Affairs. He founded and was Group Leader of the Accelerated Pipeline Chemistry Group at Amgen Inc., where he was instrumental in the advancement and development of AMG706 and Kit. Additionally, he played a major role in the discovery and development of the GT-2331/Cipralisant Maleate/Perceptin. He also founded BiophoriX. He served as an Executive Affiliate/Senior Principal for the management-consulting firm Pittiglio Rabin Todd & McGrath (acquired by PricewaterhouseCoopers). He has worked in leadership roles at Johnson & Johnson, Genentech/Roche, PricewaterhouseCoopers/PRTM and Gliatech. Mr. Handley serves on the Board of Directors of Metabiostere, Inc., nanoPharmatix Inc. and Actus Partners. He serves as the President of the Northern Colorado Bioscience Association and is an Executive-in-Residence at the Rocky Mountain Innersphere. He assisted in the launch of Avastin and Tarceva at Genentech. He holds board positions at Medavate Corp. and Symbios Technologies, Inc. Mr. Handley graduated with honors from Colorado State University with Bachelors of Science degrees in Molecular Biology, Physiology and minors in Chemistry and Neurobiology. Mr. Handley has an executive MBA program from the Graziadio School of Business and Management at Pepperdine University.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Immune Therapeutics management team in years:

7
Average Tenure
65.5
Average Age
  • The average tenure for the Immune Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Peter Aronstram

TITLE
CFO & Secretary
COMPENSATION
$70K
AGE
67
TENURE
7.3 yrs

Fengping Shan

TITLE
Chief Science Officer
AGE
60
TENURE
8.1 yrs

Mike Handley

TITLE
CEO & Director
TENURE
0.6 yrs

Gus Dalgleish

TITLE
Chief Medical Officer and Director of Research & Development
COMPENSATION
$225K
AGE
69
TENURE
6.8 yrs

Joseph Fortunak

TITLE
Vice President of Global Research & Development and Chemical Development
AGE
64
TENURE
7 yrs
Board of Directors Tenure

Average tenure and age of the Immune Therapeutics board of directors in years:

2.3
Average Tenure
65
Average Age
  • The average tenure for the Immune Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rosco Moore

TITLE
Chairman of the Board & Member of Scientific Advisory Board
COMPENSATION
$61K
AGE
65
TENURE
2.3 yrs

Mike Handley

TITLE
CEO & Director
TENURE
0.6 yrs

Nicholas Plotnikoff

TITLE
Member of Advisory Board
COMPENSATION
$16K
AGE
91

Jill Smith

TITLE
Member of Advisory Board

Clifford Selsky

TITLE
Independent Director and Member of Medical & Clinical Advisory Board
COMPENSATION
$60K
AGE
70
TENURE
4.2 yrs

Joe Chalil

TITLE
Member of Medical & Clinical Advisory Board
AGE
46
TENURE
3.6 yrs

Mak Jawadekar

TITLE
Member of Medical & Clinical Advisory Board
TENURE
3.6 yrs

Terry Grossman

TITLE
Member of Advisory Board

Gary Blick

TITLE
Member of Scientific Advisory Board
TENURE
1.7 yrs

Kevin Phelps

TITLE
Director
COMPENSATION
$10K
AGE
64
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
X
Management checks
We assess Immune Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Immune Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Immune Therapeutics, Inc., a late development-stage biopharmaceutical company, focuses on the development, commercialization, and licensing of prescription medications for humans, animals, and pets worldwide. It develops low dose naltrexone and methionine encephalin therapies for human immunodeficiency virus infections, autoimmune diseases, immune disorders, or cancer. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.

Details
Name: Immune Therapeutics, Inc.
IMUN
Exchange: OTCPK
Founded:
$7,183,971
457,577,799
Website: http://www.immunetherapeutics.com
Address: Immune Therapeutics, Inc.
37 North Orange Avenue,
Suite 800M,
Orlando,
Florida, 32801,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK IMUN Common Stock Pink Sheets LLC US USD 25. Apr 2012
Number of employees
Current staff
Staff numbers
4
Immune Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 06:32
End of day share price update: 2020/04/07 00:00
Last earnings filing: 2019/11/19
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.